FDA Licensed Ebola Virus Therapeutics
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Biomedical Advanced Research and Development Authority (BARDA), part of HHS/ASPR, is issuing a Sources Sought Notice (SSN) to gather feedback from biopharmaceutical partners regarding FDA-licensed Ebola virus therapeutics. This market research will inform potential future acquisitions and programs. Responses are due March 13, 2026.
Purpose & Scope
BARDA's mission is to protect the civilian population by developing and acquiring medical countermeasures for chemical, biological, radiological, nuclear threats, and emerging infectious diseases. This SSN specifically focuses on therapeutics licensed by the FDA for treating Ebola virus (Orthoebolavirus zairense). The information collected will serve as continued market research for possible future acquisitions and programs.
Information Requested
BARDA is requesting information from sponsors of FDA-approved Ebola virus therapeutics, including:
- Overview of Existing Therapeutic: Product type, Mechanism of Action, patient dosing regimen, and route of administration.
- Regulatory and Licensure Information: FDA licensure date, approved indications, contraindications, boxed warnings, precautions, and the FDA package insert (as an attachment).
- Manufacturing Capabilities: Ability to manufacture cGMP compliant product at 2000L scale or higher (including anticipated timelines if not currently available), and plans for improving manufacturing capacity, sustainability, and cost reduction (high-level abstract).
Submission Details
- Format: Electronic submission via the BDR Portal.
- Page Limit: Responses should be limited to five pages.
- Deadline: No later than March 13, 2026, by 3 PM US EDT.
- Registration: Respondents must register for a BDR Portal account prior to submission, as account creation may take several days.
Important Notes
This notice is for information and planning purposes only and does not obligate the U.S. Government to award a contract. No reimbursement will be provided for response costs. The U.S. Government reserves the right to use the information provided for any purpose deemed necessary. Responses to this SSN will not be considered adequate responses to a future solicitation. Proprietary information should not be included, and advisory and assistance service contractors will have access to submissions.
Contract & Timeline
- Type: Sources Sought Notice (SSN)
- Set-Aside: None specified
- Response Due: March 13, 2026, 3 PM US EDT
- Published: February 20, 2026